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Objective. Juvenile dermatomyositis (JDM) is an inflammatory pediatric myopathy characterized by focal capillary loss in muscle, followed by progressive recovery upon adequate treatment with immunomodulating drugs, although some patients remain refractory to treatment. While the underlying mechanism of capillary depletion remains uncertain, recent studies have identified an upregulation of type I interferon (IFN) expression specific to JDM. Given that myogenic precursor cells (MPCs) exert proangiogenic activity during normal skeletal muscle regeneration, we hypothesized that they may also modulate vascular remodeling/angiogenesis during JDM. The aim of this study was to investigate that hypothesis.
Methods. Human cell cocultures were used to analyze angiogenic properties in patients with JDM, patients with Duchenne's muscular dystrophy (DMD) (control patients for vascular remodeling), and healthy control subjects. Transcriptome analysis was used to examine muscle-derived MPCs. Histologic analysis of type I IFN in muscle biopsy samples was also performed.
Results. Using human cell cocultures, we showed highly angiogenic properties of MPCs from JDM patients in association with the expression of an angiogenic molecular signature. Transcriptome analysis of MPCs freshly isolated from muscle samples revealed type I IFN as the master regulator of the most up-regulated genes in JDM-derived MPCs. Functionally, treatment of normal MPCs with type I IFN recapitulated the molecular pattern and the proangiogenic functions of JDM-derived MPCs. In vivo histologic investigation showed that MPCs synthesized type I IFN and major proangiogenic molecules in JDM muscle. Moreover, MPCs derived from JDM muscles that were characterized by strong vasculopathy produced higher levels of type I IFN, confirming MPCs as a cellular source of type I IFN during JDM, and this correlated with the severity of the disease.
Conclusion. These results demonstrate a new type I IFN pathway in JDM that activates the production of angiogenic effectors by MPCs, triggering their proangiogenic function to promote vessel recovery and muscle reconstruction.
Juvenile dermatomyositis (JDM) is a heterogeneous idiopathic inflammatory myopathy of pediatric onset. Diagnostic criteria include proximal muscle weakness with increased muscle enzyme levels in the serum and distinct skin rashes. Histologic features of muscle biopsy tissue from JDM patients typically include a mixture of perivascular inflammation in the perimysium, myofiber changes, and specific microvascular alterations: capillary deposition of the complement C5b-9 membrane-attack complex and focal capillary loss (1) . Capillary loss in adult DM is present in amyopathic DM, illustrating that this event is an early hallmark of the disease (2) . Capillary loss occurs in clusters and follows a 6-by-6 capillary dropout pattern, which corresponds to the depletion of entire microvascular units (3) . The underlying mechanism of capillary depletion in JDM remains unknown.
Studies in DM have identified up-regulation of type I interferon (IFN) expression (including IFNa and IFNb) as well as of IFN-inducible genes (4), leading to the suggestion of a mechanism of myofiber and capillary injury driven by type I IFN (5). The effects of type I IFN on cells that reside within skeletal muscle are unknown, and thus, the biologic role of type I IFN in JDM remains uncertain.
JDM patients may be classified into 2 groups according to the severity of the vasculopathy. Some patients exhibit severe disease with more-severe zonal loss of muscle capillary beds, muscle infarctions, rapid therapeutic escalation requiring adjunct treatment with immunosuppressive agents, and low remission rates at 12 months (6). In contrast, a majority of patients respond to treatment with immunomodulating agents and exhibit a progressive recovery of normal muscle function (1, 6) . Recovery is associated with restoration of the normal muscle capillary bed after extensive vascular remodeling (7) .
Based on the recent findings that myogenic precursor cells (MPCs) (derived from muscle stem cells, or satellite cells) exhibit proangiogenic activity during normal muscle regeneration (8, 9) , we hypothesized that MPCs may play specific roles during JDM through cooperation with endothelial cells (ECs). We investigated the features of human MPCs isolated from JDM patient muscle via functional experiments and high-throughput molecular analyses. We established the angiogenic properties of JDM-derived human MPCs. Transcriptome analysis identified type I IFN as a major regulator of gene expression in JDM-derived MPCs. Treating normal MPCs with type I IFN recapitulated the features of JDM-derived MPCs.
Furthermore, in vivo and in vitro investigations showed that MPCs synthesized type I IFN during JDM, which correlated with the severity of the disease.
PATIENTS AND METHODS
Patients. The JDM patients (n = 12) met the diagnosis according to conventional clinicopathologic criteria (10) . The diagnosis of genotyped patients with Duchenne's muscular dystrophy (DMD; n = 10) was established based on a total absence of dystrophin. Biopsy samples from DMD and JDM patients were obtained from the deltoid muscle at the time of diagnosis. Normal control biopsy samples were obtained from the paravertebral muscle of patients undergoing spinal arthrodesis (n = 16). All biopsy samples were blindly reviewed for clinical data, using the validated scoring tool for muscle biopsy evaluation in JDM patients (11) . Additional details about the study population and study methods are given in the Supplementary Methods document (available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40328/abstract).
Immunohistochemical analysis. Immunohistochemistry of muscle biopsy sections was carried out as previously described (12) using anti-CD31, anti-CD56, anti-type I IFN, anti-CCL2, and anti-interleukin-6 (anti-IL-6) antibodies, which were revealed using fluorescein isothiocyanate-or Cy3-conjugated secondary antibodies. For controls, primary antibodies were replaced with IgG or irrelevant antibodies (see Supplementary  Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40328/abstract).
Culture of human MPCs and human dermal microvascular ECs (HDMECs). Pediatric MPCs were isolated from skeletal muscle samples obtained from normal subjects, JDM patients, and DMD patients. Cells were obtained and cultured as previously described (13) in Ham's F-12 medium (Gibco) containing 15% fetal bovine serum (Ham's F-12 growth medium) and were sorted at the first passage with anti-CD56 magnetic beads (Miltenyi Biotec) according to the manufacturer's instructions. The purity of the cells was assessed according to CD56 expression (ref. no. 555518; BD PharMingen), as determined by flow cytometry. All cell cultures were performed at 37°C in an atmosphere of 5% CO 2 . Absence of hematopoietic cells (CD45+) was determined as described in Supplementary Figure 2A (at http://onlinelibrary. wiley.com/doi/10.1002/art.40328/abstract). No difference in the growth rate or differentiation was observed between MPCs from control subjects and those from JDM patients.
HDMECs were purchased from PromoCell and were checked for the absence of hematopoietic cells (CD45+) (see Supplementary Figure 2A ). For all experiments (except for the migration assay), cells were seeded onto type I collagencoated (rat tail collagen diluted 1:100; Invitrogen) support and cultured in the recommended medium.
Cell migration and EC proliferation assays. Migration was performed using double chamber inserts (Ibidi/ Applied BioPhysics). One chamber was filled with MPCs, and the other chamber was seeded with ECs. After 3 days, the silicone walls of the chambers were removed. The gap between the 2 migration fronts was imaged at time 0 and at 24 hours.
For proliferation assays, ECs were incubated for 36 hours in the presence or absence of MPC-conditioned medium. Cells were then labeled with anti-Ki-67 antibodies, which were revealed with the use of Cy3-conjugated secondary antibodies.
Fibrin gel bead 3-dimensional angiogenesis assay. Threedimensional fibrin gel assays were carried out as previously described (14) . EC-coated beads were seeded in fibrin gels. Fibroblasts or MPCs were then seeded on top of the gel, and bead assays were monitored for 6 days. Photomicrographs of the beads were captured to analyze capillary length, numbers, and lumenization. In some experiments, MPCs or fibroblasts were cultured for 48 hours in the presence of 20 ng/ml of IFNb or IFNa (PeproTech) before seeding.
Angiogenesis protein array. MPCs were obtained from normal, JDM, and DMD muscle samples. In some experiments, normal MPCs were treated for 24 hours with 20 ng/ml of IFNb or were incubated for 24 hours in hypoxic GenBag Microaer (3% oxygen) chambers (BioM erieux) and/or in either low-glucose Dulbecco's modified Eagle's medium (DMEM) (ref. no. 21885; Gibco) or no-glucose DMEM (ref. no. 11966; Gibco) to mimic a hypoxic/ischemic environment. Cells were collected in lysis buffer, and proteins were processed on Human Angiogenesis Antibody Array C1000 membranes (RayBiotech) according to the manufacturer's instructions.
Transcriptome analysis of human MPCs and ECs. Fresh muscle biopsy samples from normal subjects or JDM patients were minced and digested. Cells were incubated with an anti-CD31 and anti-CD56 antibodies, further sorted using a FACSAria III instrument (Becton Dickinson), and immediately treated with TRIzol reagent. The number of recovered cells was 13,000-60,000 and 21,000-60,000 for CD56+ and CD31+ cells, respectively. Total RNA (125 pg) was reverse transcribed according to the Ovation Pico WTA System V2 (NuGEN). The resulting double-stranded complementary DNA was used for hybridization to GeneChip Human Gene 2.0 ST arrays (Affymetrix). After normalization, quality control, and statistical analysis, differentially expressed genes were identified by two-way analysis of variance (15) (Supplementary Table 1 , available at http://onlinelibrary.wiley.com/doi/10.1002/art.40328/ abstract). Functional analyses were carried out using DAVID (16) and REVIGO (17) bioinformatics tools. Data are deposited in the GEO database at NCBI (accession no. GSE66845).
Quantification of IFNa in MPC lysates by single-molecule assay (Simoa). MPCs were grown in Ham's F-12 growth medium, and 70,000-500,000 cells were lysed in radioimmunoprecipitation buffer. The Simoa IFNa assay was developed using a Quanterix Homebrew Simoa assay according to the manufacturer's instructions, and with 2 autoantibodies specific for IFNa, which were isolated and cloned from 2 patients with autoimmune polyglandular syndrome type I (APS-I)/autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) that were recently described (18, 19) .
Statistical analysis. All experiments were performed at least 3 times. Results were analyzed by t-test and analysis of variance (ANOVA), as indicated below. P values less than 0.05 were considered significant.
RESULTS
MPC comparison groups. The properties of MPCs derived from the muscles of patients with JDM were compared with those of MPCs derived from the muscles of normal subjects and patients with DMD (control for vascular remodeling). DMD is characterized by cycles of necrosis/regeneration that are associated with vascular alterations but without muscle recovery (20) .
Specific proangiogenic activity of MPCs from JDM patients. We used a 3-dimensional angiogenic assay that recapitulates the key stages of angiogenesis up to the formation of an intraluminal compartment, which allowed for assessment of complete differentiation of the capillary structures that are formed (14) ( Figure   T2 1A). As compared 
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GITIAUX ET AL Figure 2 . Angiogenic signature of myogenic precursor cells (MPCs) derived from muscle biopsy samples obtained from juvenile dermatomyositis (JDM) patients, Duchenne's muscular dystrophy (DMD) patients, and normal (NM) subjects. MPCs were analyzed for their expression of 43 angiogenesis-related molecules using antibody arrays. Results are the fold change in expression of the indicated molecules in muscle-derived MPCs from A, JDM patients versus normal subjects, B, DMD patients versus normal subjects, and C, DMD patients versus JDM patients. The fold change in expression was calculated from the mean expression in the muscles of 4 different subjects per group. P values were determined by twoway analysis of variance. EGF = epidermal growth factor; bFGF = basic fibroblast growth factor; IGF-1 = insulin-like growth factor 1; PDGF-BB = platelet-derived growth factor BB; PLGF = placental growth factor; VEGF = vascular endothelial growth factor; G-CSF = granulocyte colony-stimulating factor; GM-CSF = granulocyte-macrophage colony-stimulating factor; THPO = thrombopoietin; ANGPT1 = angiopoietin 1; ANG = angiogenin; IFNc = interferon-c; IL-6 = interleukin-6; TNFa = tumor necrosis factor a; TGFb1 = transforming growth factor b1; I-TAC = interferon-inducible T cell a chemoattractant (CXCL11); PLG = plasminogen; ENA-78 = epithelial neutrophil-activating peptide 78 (CXCL5); GRO = growth-related oncogene a (CXCL1); MCP-1 = monocyte chemotactic protein 1 (CCL2) (also, MCP-3 [CCL7]; MCP-4 [CCL13]); I-309 = inflammatory cytokine I-309 (CCL1); MMP-1 = matrix metalloproteinase 1; TIMP-1 = tissue inhibitor of metalloproteinases 1; uPAR = urokinase-type plasminogen activator receptor; PECAM-1 = platelet endothelial cell adhesion molecule 1 (CD31); TIE-2 = tyrosine protein kinase receptor 2 (CD202B); VEGFR-2 = vascular endothelial growth factor receptor 2.
TYPE I IFN-DRIVEN PROANGIOGENIC PROPERTIES OF MPCs IN JDM
with MPCs derived from normal muscle, MPCs from JDM patients showed significantly increased capillary lengths on day 6 (+128%), while those from DMD patients also exhibited the capacity to promote tube formation ( Figure   T2 1B). The number of capillaries formed per bead was not significantly altered under either condition ( Figure   T2 1C). However, the formation of capillaries exhibiting a lumen was strongly increased in MPCs from JDM patients (+180%). In contrast, capillary morphogenesis was decreased in MPCs from DMD patients (-39%) ( Figure   T2 1D Figure 3D , available at http://onlinelibrary.wiley.com/doi/10.1002/art.40328/ abstract). These results show that MPCs from JDM patients displayed efficient proangiogenic activity that triggered capillary elongation and lumenization.
Specific proangiogenic signature of MPCs from JDM patients. In order to define the angiogenic molecular signature of MPCs derived from the muscles of JDM patients, the expression of 43 angiogenesis-related proteins was evaluated using an antibody array and then compared with that of MPCs derived from the muscles of normal subjects or DMD patients. Two-way ANOVA showed that the angiogenic signature of MPCs from JDM patients significantly differed from that of MPCs from normal subjects ( Figure Figure 9B) . 138 GITIAUX ET AL 
These transcriptome data correlate well with type I IFN being a major specific signature of JDM at disease onset (4, 21, 25, 26) . They further show for the first time at the cellular level that both MPCs and ECs exhibit in situ a preponderant, yet dissimilar, type I IFN response during JDM.
Normal MPCs treated with type I IFN mimic the proangiogenic activity of MPCs from JDM patients. To determine the molecular mechanisms underlying the proangiogenic effects of MPCs from JDM patients, we attempted to mimic in vitro the conditions encountered by MPCs in the presence of JDM. Hypoxia and ischemia have been associated with JDM (27) and are known to induce angiogenesis. MPCs derived from the muscle of normal subjects were therefore cultured under conditions of hypoxia or hypoxia combined with glucose-free medium (thereby mimicking ischemic conditions). Production of angiogenic molecules was evaluated as above using an antibody array. As shown in Figures   T2 3A and B, MPCs under hypoxic or ischemic conditions showed similar regulation of 49% and 51% of the proteins in the array, respectively. Among these, 63% and 53% were up-regulated as in the Up-regulation of IFNb, CCL2, and IL-6 expression by MPCs and ECs in JDM patients. To confirm the in vivo relevance of type I IFN signaling that is operant in JDM, immunolabeling was performed on muscle sections obtained from normal subjects and JDM patients. We analyzed IFNb as well as 2 major angiogenic proteins expressed by MPCs in vitro: IL-6 and MCP-1/CCL2 (Figure   T2 2), which have been shown to be elevated in sera from JDM patients (21, 22) . Figure   T2 5A shows that in normal muscle, 46% of satellite cells (CD56+ cells) expressed IFNb, while in JDM muscle, 86% of satellite cells and active myogenic cells strongly expressed IFNb. Similarly, CCL2 and IL-6 were only partly expressed by satellite cells in normal muscle (50% and 25%, respectively), while the majority of CD56+ cells were positive for IL-6 and CCL2 staining in JDM muscle (86% and 66%, respectively) ( Figure   T2 5A). In normal muscle, ECs (CD31+ cells) partly expressed IFNb, IL-6, and CCL2 (21%, 38%, and 26%, Figure 5 . In vivo expression of IFNb, IL-6, and CCL2 by myogenic and endothelial cells. Top, Muscle biopsy sections from normal subjects and JDM patients were processed for double immunolabeling for A, CD56, which identifies myogenic precursor cells (green), or B, CD31, which identifies endothelial cells (green), and for IFNb, IL-6, and CCL2 (24) . 
). In JDM, the vast majority of cells identified as ECs strongly expressed IFNb, IL-6, and CCL2 (83%, 83%, and 75%, respectively) (Figure T2 5B). It should be noted that other cell types not labeled by CD31 or CD56 antibodies also express these proteins and likely include interstitial cells, inflammatory cells, and notably, plasmacytoid dendritic cells, which are known to produce IL-6, CCL2, and IFNb (25, (28) (29) (30) (31) . These in vivo results show that MPCs and, to a lesser extent, ECs up-regulate IFNb, IL-6, and MCP-1/CCL2, which suggests their participation in an autocrine way in the activation of the type I IFN response during JDM.
Correlation between IFNa secretion by MPCs from JDM patients and disease severity. To validate the production of type I IFN by MPCs, we used Smoa, a novel single-molecule assay that we recently developed with high-affinity autoantibodies isolated from APECED patients (18, 19) . It allows the detection of attomolar concentrations of IFNa in human fluids or in isolated human cells (technique is not yet available for IFNb). Figure   T2 6A shows that the IFNa protein levels in MPCs derived from JDM patients exhibiting a low vascular score, i.e., little or no vascular abnormalities according to consensus JDM scoring (11) , was similar to that of MPCs derived from normal muscle. However, IFNa protein levels in MPCs from JDM patients was significantly higher (5.7-8.3-fold) in cells that originated from muscles with a high vascular score, i.e., strong capillary loss, arterial abnormalities, and microinfarcts (11) ( Figure   T2 6A). This was confirmed by the significant positive correlation between IFNa protein in MPCs from JDM patients and the severity of the vascular injury in the muscles from which they were derived ( Figure   T2 6B). These results are the first to demonstrate MPCs as a source of IFNa during JDM.
DISCUSSION
Skeletal muscle regeneration is associated with vascular remodeling, since myogenesis and angiogenesis take place concomitantly in the muscle tissue (9) . Given their close topographic proximity in skeletal muscle (8) , ECs and MPCs interact with each other, and several in vitro studies found evidence of the direct angiogenic properties of MPCs toward ECs through the delivery of a series of effectors (8, 32) . In the present study, we found that MPCs derived from the muscles of JDM patients exerted a strong proangiogenic effect that induced in vitro the migration and proliferation of ECs, as well as capillary morphogenesis. This proangiogenic property was supported by the production of angiogenic factors by MPCs from JDM patients. In vivo, MPCs from the muscles of JDM patients exhibited a type I IFN-driven molecular signature and expressed IFNb and the IFN-regulated effectors CCL2 and IL-6. In vitro treatment of normal MPCs under hypoxic conditions or with type I IFN mimicked the angiogenic signature of MPCs from JDM patients and phenocopied the proangiogenic properties of MPCs from JDM patients. Finally, the production of IFNa by MPCs, which correlated positively with the severity of the vasculopathy (and thus, with the severity of the disease), was substantiated.
Taken together, these data support a role of the proangiogenic activity of MPCs driven by type I IFN in the stimulation of vessel remodeling and muscle recovery, thereby indicating a new function of type I IFN in the pathogenesis of JDM. While MPCs obtained from normal subjects and JDM patients were derived from different muscle sources (paravertebral and deltoid muscles, respectively), it is unlikely that muscle origin accounted for the behavior of the cells because: 1) we did not observe variations in cell growth and differentiation in culture, 2) MPCs from DMD patients, which were derived from deltoid muscles, exhibited a different phenotype, affecting the lumenization of capillaries in vitro, and 3) type I IFN treatment of MPCs from the paravertebral muscles of normal subjects recapitulated the molecular signature and function of MPCs from the deltoid muscles of JDM patients, both in vitro and ex vivo.
Type I IFN is a major marker and signaling regulator in DM and JDM. Several studies using whole muscle extracts or blood samples from patients identified an IFNb signature, which was correlated with disease severity (4, 21, 25, 26) . Consequently, treatment of DM patients with anti-IFNb decreases this IFNb signature, both in blood and in muscle (33) . Consistent with a major role of type I IFN in JDM, our data show that the highly proangiogenic properties of JDM-derived MPCs were due to the production of a panel of IFN-induced angiogenic effectors; among them, CCL2/MCP-1 and IL-6 were highly expressed. The role of CCL2 and IL-6 in angiogenesis is well established, including in skeletal muscle (34, 35) . CCL2 belongs to the type I IFN-induced proteins that are up-regulated in DM in parallel with capillary loss and DM severity (21, 22, (36) (37) (38) (39) . Similarly, IL6 gene expression in muscle and IL-6 protein levels in the circulation have been shown to correlate with the type I IFN signature and with disease activity (21, 22) . In the same way, the increased expression of IFITM1 (4.7 fold increase; P = 0.018) (Supplementary Table 1 , available at http://onlinelibrary.wiley.com/doi/10.1002/art.40328/ab stract), which is essential for vessel lumenization (40) , could account for the efficiency of MPCs from JDM patients to promote complete capillary morphogenesis.
With regard to ECs, we observed that JDM-derived ECs highly expressed S100A8/MRP8, S100A9/MRP-8/14, and S100A12/MRP6, which also correlated with the severity of the disease (22, 41, 42 ). An unbalanced production of MRP-8/14 by activated ECs could confer thrombogenic and apoptotic properties on ECs (23), suggesting the maintenance of vascular injury via autocrine secretion of antiangiogenic factors. Along the same line, the angiostatic effectors CXCL9 (monokine induced by IFNc [MIG]), CXCL10 (IP-10), and CXCL11 (I-TAC), which are type I IFN-inducible chemokines the expression of which correlates with the severity of DM (36, 38, 39) , were shown here to be strongly up-regulated in JDM at the cellular level only in ECs (125-fold more [P < 0.0001] and 41-fold more [P = 0.001] for CXCL10 and CXCL1, respectively). These angiostatic effectors limit EC migration and proliferation and are considered to be hallmarks of EC damage in JDM. Our results indicate that in JDM, MPCs express a specific type I IFN angiogenic signature, whereas ECs exhibit a type I IFN-associated antiangiogenic signature, which is consistent with the vasculopathy observed in the disease.
Treatment of normal MPCs with IFNa/b triggered the expression of proangiogenic factors, phenocopying the proangiogenic properties observed in MPCs from JDM patients. In a previous study, IFNb-treated human myogenic cells were shown to up-regulate the expression of a series of type I IFN-inducible genes (HERC5,  HERC6, IFI27, IFI44L, IFI6, IFIH1, IFIT1, IFIT3, MX1,  MX2, OAS1, OAS2, OAS3 , and RASD2) (5). These 14 genes are among the ones we found to be the most highly up-regulated in MPCs freshly isolated from JDM muscle (Supplementary Figure 9 , available at http://onlinelibra ry.wiley.com/doi/10.1002/art.40328/abstract). Moreover, major histocompatibility complex class I-positive microdissected myofibers from DM patients (excluding inflammatory cells from the analysis) have been shown to exhibit a similar type I IFN signature that is specific to DM (10 of the 18 IFN-induced up-regulated genes in isolated JDM-derived MPCs) (43) . These data clearly establish type I IFN as a major signaling pathway in JDM MPCs that trigger proangiogenic properties in these cells, thereby promoting angiogenesis.
It is now accepted that type I IFN and the abovecited type I IFN-related inflammatory effectors are biomarkers of DM and of its severity (4, 21, 22, 26, 41) , and our data demonstrate that IFN-derived MPCs are correlated with the severity of the vasculopathy. However, the mechanisms by which type I IFN-induced gene products are involved in the pathogenesis of JDM remain unclear, and it is likely that type I IFN acts in both detrimental and beneficial ways. On the one hand, it has been shown that type I IFN induces antiangiogenic pathology in ECs through an IFN/IL-18 axis (44), consistent with several studies demonstrating toxic, antiproliferative, and antiangiogenic effects of type I IFN on ECs (45, 46) . On the other hand, ISG15, a ubiquitin-like modifier that is the second most up-regulated gene in MPCs from JDM patients, was recently shown to be a key negative regulator of type I IFN immunity, thereby preventing autoinflammatory consequences of uncontrolled type I IFN amplification (15) . Moreover, ISG15 silencing does not reverse type I IFN-mediated toxicity, which is evidence against it being a major factor in mediating the myotoxic effects of type I IFN (47), as it was previously thought to be after its detection in areas of DM pathologic activity, such as perifascicular atrophic myofibers (5). Our study showing the highly increased production of IFNa by MPCs originating from muscles exhibiting severe disease identifies MPCs as a cellular source of type I IFN in JDM, just as they are in adult DM (48) . These data also suggest an autocrine/ paracrine action of type I IFN on MPCs, which is triggered by the extent of the vascular damage and leads to their proangiogenic action.
Besides type I IFN signaling and because of the vascular damage, hypoxia-related pathology due to vascular changes (inflammatory vasculopathy) has also been recognized as an important additional mechanism in DM (3). In particular, perifascicular atrophy is invariably TYPE I IFN-DRIVEN PROANGIOGENIC PROPERTIES OF MPCs IN JDMassociated with ischemia due to capillary reduction and vessel damage (49, 50) . Hypoxia and hypoxia-inducible factor pathways have been detected in DM (51) and seem to be important in JDM (27) . Accordingly, culturing normal MPCs under conditions of hypoxia or ischemia partially mimicked the proangiogenic signature seen in JDM, suggesting that hypoxia partly explains the proangiogenic signature observed in MPCs from patients with JDM.
In conclusion, while the precise role of the type I IFN pathway and type I IFN-inducible genes in JDM is still to be deciphered, as well as the roles of the genes triggered by hypoxic/ischemic cues, our study provides the first evidence of a specific type I IFN-driven signaling pathway at work in MPCs that is different from that in ECs derived from the same muscle. Moreover, immunohistochemical analysis identified MPCs and ECs as cellular sources of IFNb during JDM, and Simoa analysis clearly identified MPCs as a cellular source of IFNa during severe vasculopathy, suggesting an autocrine/paracrine action of type I IFN in MPCs and ECs. Our in situ analysis, however, identified other cell types that are likely involved in IFNb production. Plasmacytoid dendritic cells are present in JDM muscle (29) and express type I IFN (25) . Thus, analysis at the cellular level will be required in order to evaluate the relative contributions of the various cell types that are present in the skeletal muscles of patients with JDM, including resident and recruited inflammatory cells, and to decipher the complexity of type I IFN signaling from and toward these cell partners.
Our study suggests that type I IFN drives on the one hand an antiangiogenic response in ECs, which may participate in-or maintain-the vasculopathy that characterizes JDM, and on the other hand a strong proangiogenic response in MPCs, triggering an efficient proangiogenic activity toward ECs, likely participating in the restoration of the vascular bed and therefore muscle function. In this context, therapeutic targeting of type I IFN may be cautiously viewed as a way to avoid blunting the beneficial effects of this pathway in JDM.
